Griffithsin (GRFT) Fast-Dissolving Insert (FDI)

The Griffithsin (GRFT) fast-dissolving insert (FDI) is developed by Population Council. This fast-dissolving vaginal insert is an on-demand HIV prevention product for women and girls, including pregnant and breastfeeding women, designed for over-the-counter distribution as a non-antiretroviral option. Manufacturable in low- and middle-income countries, the safe, discreet, user-controlled, and portable fast-dissolving insert has activity against HIV, HSV-2, and HPV, and may be suitable for over-the-counter distribution. Building on favorable outcomes in animal models, the GRFT FDI will be advanced through pre-clinical studies, production of good manufacturing practice FDIs, and the conduct of Phase 1 trials.

Cabotegravir Pellet Implant with Levonorgestrel

The cabotegravir pellet implant with levonorgestrel is a long-acting multipurpose prevention technology implantable product developed by CONRAD combining cabotegravir, for HIV prevention, and levonorgestrel, for contraception, in a biodegradable subdermal pellet system. This product is a low-cost, biodegradable subdermal pellet-type implant system that provides tightly controlled, long-acting sustained release of its payload, is highly tunable, and does not require surgical removal.

*Also referred to as a dual-prevention product by MATRIX

Non-ARV/Non-Hormonal Multi-Purpose Vaginal Ring

The non-antiretroviral, non-hormonal intravaginal ring developed by the Oak Crest Institute of Science is a multipurpose prevention technology with a 1-to 3-month duration combining two novel, luminally acting active pharmaceutical ingredients: (1) an anti-viral with unique mechanisms of action against HIV, HSV, and HPV; and (2) a contraceptive and would be a game-changer product for women who desire non-hormonal contraceptives with prevention of HIV and other sexually transmitted infections in a single product. Gathering end-user feedback early in the design phase will be prioritized. First-in-human trials will evaluate the safety and pharmacokinetics of the multipurpose prevention technology.

Dapivirine/Levonorgestrel Extended-Release Monthly Film

The multipurpose prevention technology (MPT) vaginal film being developed by the Rohan Pharmaceutics laboratory at the University of Pittsburgh School of Pharmacy and Magee-Womens Research Institute is a product providing monthly protection against HIV acquisition and unintended pregnancy. Building upon their innovative bioerodible vaginal film platform, this MPT product is being developed as a convenient, low-cost option with desirable features that are informed through end-user acceptability research. The product will undergo formulation optimization, preclinical testing (including studies in animal models such as macaques), IND-filing, and clinical testing in women.

Novel Intravaginal Ring as a Non-Hormonal Contraceptive Multipurpose Prevention Technology (MPT)

The Population Council and partners are advancing the development of a non-hormonal vaginal ring with potential to provide contraception along with broad microbial action against bacterial vaginosis-associated bacteria, HIV, HSV-2, chlamydia, and gonorrhea. This ring will also be designed with the added benefit of promoting vaginal health by helping to maintain optimal vaginal pH and reducing symptoms of bacterial vaginosis.

Dual Prevention Pill (DPP) / TELE

The proposed product is a fixed-dose combination (FDC) tablet of TDF / FTC / LNG / EE indicated for both the prevention of HIV and pregnancy.  The product will be supplied as a 28-count blister compliance pack containing 21 tablets of the fixed-dose combination of TDF, FTC, LNG, and EE (a 3-week supply) plus 7 tablets of FTC and TDF (a 1-week supply).

Q-Griffithsin (Q-GRFT) Enema

This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse. GRFT is one of the most powerful, broad-spectrum antivirals ever tested and its activity is under study for potential therapeutic applications against several viral pathogens including HIV, herpes simplex virus type-2, human papillomavirus (HPV), and hepatitis C. For the purposes of this study GRFT has been genetically modified to produce a more stable compound less prone to oxidation, Q-GRFT

Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)

First-in-line, ultra-long-acting injectable MPT that offers durable and sustained protection from HIV transmission, high efficacy of contraception, increased user compliance, and the ability to be removed. It consists of a liquid MPT formulation utilizing excipients that form a biodegradable depot after subcutaneous injection (in-situ forming implant (ISFI)).